|Articles|October 25, 2021
Pharmacy Clinical Pearl of the Day: Bulimia Nervosa
Author(s)Saro Arakelians, PharmD
Patients with bulimia may use different methods to get rid of calories and prevent weight gain, such as self-inducing vomiting on a regular basis.
Advertisement
Clinical Pearl of the Day: Bulimia Nervosa
Bulimia nervosa, commonly called bulimia, is a serious, potentially life-threatening eating disorder.
Insight:
- People with bulimia may secretly binge and eat large amounts of food and then purge.
- Patients may use different methods to get rid of the calories and prevent weight gain, such as self-inducing vomiting on a regular basis, misuse of laxatives, weight loss supplements, diuretics or enemas, strict dieting, or excessive exercise routines.
- Symptoms include being overly pre-occupied with body shape and weight; living in fear of gaining weight; eating large amounts of food and forcing vomiting; using laxatives, diuretics, or enemas; fasting; restricting calories; and using dietary supplements or herbal products to lose weight.
- Risk factors include people focused on dieting, patients with family history, or people with psychological and mental disorders, such as anxiety and depression.
- Treatment options would include coping and support, learning about bulimia, getting the right nutrition, being cautious with exercise, dietary supplements and herbs.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5